BOSTON, June 27 /PRNewswire-FirstCall/ -- New data offer hope for migraine
sufferers who report that they have poor response or are intolerant to their
migraine therapy. Two studies of migraineurs who reported that they had poor
response to, or did not tolerate, short-acting triptans, showed that treatment
with Treximet provided sustained pain-free results at two through 24 hours and
was generally well-tolerated. These studies were presented today at the 50th
Annual Scientific Meeting of the American Headache Society in Boston.
'This information is important to people who have tried and have not yet
found relief from short-acting triptans,' stated Ninan Mathew, M.D., director
of the Houston Headache Clinic and lead author of the study. 'Patients often
need to try several medications before finding a therapy that is effective.
Migraine sufferers should not be discouraged if the first treatment they try
doesn't provide the relief they need, but rather should speak with their
doctor and re-evaluate their migraine treatment.'
These data also underscore the benefits of Treximet, a prescription
treatment that addresses both the early and late stages of a migraine.
Treximet, the only migraine treatment designed to target multiple mechanisms
of migraine by combining a triptan and an anti-inflammatory pain reliever in a
single tablet, was approved by FDA in April of this year.
About the Studies
The data are from two identical randomized multi-center, double-blind,
placebo-controlled crossover trials that evaluated 283 men and women who
typically had a history of four to five migraines each month. Subjects in
these studies had, on average, a 22 to 24-year history of migraine without
aura and reported that they had discontinued treatment with a short-acting
triptan due to poor response or intolerance within the past year. Subjects
were randomized to receive Treximet or placebo and were instructed to treat
within an hour of onset of the migraine while the headache pain was still
mild.
In both studies:
-- Treximet was superior to placebo in producing sustained pain-free
results from two through 24 hours (26 percent vs. 8 percent in Study 1; and 31
percent vs.
